Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PARP-1–Targeted Auger Emitters Display High-LET Cytotoxic Properties In Vitro but Show Limited Therapeutic Utility in Solid Tumor Models of Human Neuroblastoma

1 Nov 2019

Abstract excerpt

The currently available therapeutic radiopharmaceutical for high-risk neuroblastoma, 131I-metaiodobenzylguanidine, is ineffective at targeting micrometastases because of the low–linear-energy-transfer (LET) properties of high-energy β-particles. In contrast, Auger radiation has high-LET properties with nanometer ranges in tissue, efficiently causing DNA damage when emitted near DNA. The aim of this study was to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Neuroblastoma Research and Treatments
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31676730
DOI: 10.2967/jnumed.119.233965

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PARP-1–Targeted Auger Emitters Display High-LET Cytotoxic Properties In Vitro but Show Limited Therapeutic Utility in Solid Tumor Models of Human NeuroblastomaPMID 31676730Read ↗

Targeting PARP-1 with Alpha-Particles Is Potently Cytotoxic to Human Neuroblastoma in Preclinical ModelsSemantic proximity Read ↗

PARP Theranostic Auger Emitters Are Cytotoxic in BRCA Mutant Ovarian Cancer and Viable Tumors from Ovarian Cancer Patients Enable Ex-Vivo Screening of Tumor ResponseSemantic proximity Read ↗

Advancements in PARP1 Targeted Nuclear Imaging and Theranostic ProbesSemantic proximity Read ↗

Overcoming Resistance of Glioblastoma to Conventional Cytotoxic Therapies by the Addition of PARP InhibitorsSemantic proximity Read ↗

DNA Repair Enzyme Poly(ADP-Ribose) Polymerase 1/2 (PARP1/2)-Targeted Nuclear Imaging and RadiotherapySemantic proximity Read ↗

Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation TherapySemantic proximity Read ↗

Molecular Imaging: PARP-1 and BeyondSemantic proximity Read ↗

A Radiotracer Strategy to Quantify PARP-1 Expression <i>In Vivo</i> Provides a Biomarker That Can Enable Patient Selection for PARP Inhibitor TherapySemantic proximity Read ↗

A novel <sup>18</sup> F-labeled brain penetrant PET ligand for imaging poly(ADP-ribose) polymerase-1Semantic proximity Read ↗

Molecular Imaging of PARPSemantic proximity Read ↗

Single cell resolution in vivo imaging of DNA damage following PARP inhibition.Semantic proximity Read ↗

Optical Imaging of PARP1 in Response to Radiation in Oral Squamous Cell CarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.